Actively Recruiting

Phase 2
Age: 18Years - 65Years
All Genders
ID05243654

Efficacy and Tolerability of Adjunct Metformin in Combination With Multidrug Treatment for Multibacillary Leprosy: A Randomized Double-blind, Controlled Proof-of-Concept Phase 2 Trial in Indonesia

Led by Oxford University Clinical Research Unit Indonesia · Updated on 2025-08-07

166

Participants Needed

6

Research Sites

4 weeks

Total Duration

On this page

Sponsors

O

Oxford University Clinical Research Unit Indonesia

Lead Sponsor

U

University of Gadjah Mada, Faculty of Medicine

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the safety, tolerability, and effectiveness of adding metformin to standard multidrug therapy (MDT) for patients newly diagnosed with multibacillary leprosy. This double-blind, placebo-controlled Phase 2 trial aims to see if metformin can reduce leprosy reactions, nerve damage, and corticosteroid use while assessing immunological responses. The study is supported by the Leprosy Research Initiative and conducted in Indonesia with participants aged 18 to 65. Participants will be randomly assigned to receive either metformin or a placebo once daily. Metformin dosing starts at 500mg for two weeks, then increases to 1000mg for 22 weeks, alongside 48 weeks of standard MDT. The placebo group receives matching tablets to maintain blinding. The trial plans to enroll 166 patients to compare clinical outcomes between the two groups. During the 48-week study, participants will be regularly monitored for leprosy reactions, adverse events, nerve function, corticosteroid use, and quality of life through clinical assessments and questionnaires. The primary outcomes include the proportion of patients experiencing leprosy reactions and adverse events within specified timeframes. Secondary outcomes focus on reaction severity, timing, frequency, and impact on daily living. Safety and tolerability will also be closely observed throughout the study period.

CONDITIONS

Brief Title

Efficacy and Tolerability of Adjunct Metformin for Multibacillary Leprosy

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participant is a male or female, aged 6518 and 6465 years.
  • Participant is newly diagnosed with MB leprosy and has been receiving MDT 64 28 days.
  • Participant is willing and able to give informed consent for participation in the trial.
  • Participant is willing to adhere to study follow-up schedule for 48 weeks.
Not Eligible

You will not qualify if you...

  • Participant has received MDT >28 days for the current episode of MB leprosy, prior to study enrolment.
  • Presence of leprosy reaction and/or nerve function impairment requiring systemic corticosteroids on screening/enrolment evaluation.
  • Participants who have been treated for leprosy in the past.
  • Chronic systemic corticosteroid use for any other medical condition on screening evaluation (chronic use defined as 651 2 weeks).
  • History of diabetes mellitus or diabetes mellitus diagnosed on screening evaluation (random blood glucose is elevated 65200 mg/dL (or 6511,1 mmol/L) or fasting blood glucose 65126 mg/dL (or 657.0 mmol/L)).
  • History of hypoglycaemia (random blood glucose <55 mg/dL (or <3.0 mmol/L)).
  • History of cardiac failure, ischaemic heart disease, alcoholism, history of lactic acidosis or states associated with lactic acidosis such as shock or pulmonary insufficiency, and conditions associated with hypoxia.
  • History of intolerance or hypersensitivity to metformin.
  • Estimated glomerular filtration rate (eGFR) 6430 mL/min/1.73m2 calculated by the CKDEPI equation.
  • AST or ALT 653 times the upper limit of normal (ULN) on screening evaluation.
  • Any serious medical condition for which participation in the trial, as judged by the investigator or treating physician, could compromise the well-being of the subject or prevent, limit or confound protocol-specified assessments.
  • HIV-positive on screening evaluation.
  • Female participant of childbearing age who is pregnant (clinically confirmed or urine dipstick for human chorionic gonadotrophin hormone) or breastfeeding.
  • Use of metformin within 12 weeks prior to study enrolment.
  • Use of other regular hypoglycaemic agents, including insulin.
  • Participation in another research trial involving an investigational product within 12 weeks prior to study enrolment.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 24 weeks

Participants receive either metformin or placebo in combination with standard multidrug therapy (MDT) for multibacillary leprosy to evaluate efficacy, safety, and tolerability.

Regular visits during the 24-week treatment period

Follow-up

Duration - 24 weeks

Participants are followed for safety and to assess leprosy reactions and quality of life up to the end of the 48-week study period.

Regular visits during the 24-week follow-up period after treatment

Trial Site Locations

Total: 6 locations

1

Sitanala Leprosy Hospital

Tangerang, Banten, Indonesia, 15121

Actively Recruiting

2

Palangga Health Center

Makassar, South Sulawesi, Indonesia, 92161

Actively Recruiting

3

Bajeng Health Center

Makassar, South Sulawesi, Indonesia, 92211

Actively Recruiting

4

Abe Pantai Community Health Center

Jayapura, Special Region of Papua, Indonesia

Actively Recruiting

5

Hamadi Community Health Center

Jayapura, Special Region of Papua, Indonesia

Withdrawn

6

Jayapura Utara Community Health Center

Jayapura, Special Region of Papua, Indonesia

Actively Recruiting

Loading map...

Research Team

M

Marlous Grijsen, MD, PhD

M

Mutia Rahardjani, MD, MSc

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Metformin as adjunctive therapy in combination with multidrug treatment for multibacillary leprosy: A protocol for a randomized double-blind, controlled Phase 2 trial in Indonesia (MetLep Trial).

Hana Krismawati, Sri V Muchtar, Mutia Rahardjani...

https://pubmed.ncbi.nlm.nih.gov/38808319